Systematic Financial Management LP Grows Stock Position in Innoviva, Inc. (NASDAQ:INVA)

Systematic Financial Management LP raised its position in Innoviva, Inc. (NASDAQ:INVA) by 4.7% during the third quarter, Holdings Channel reports. The firm owned 1,979,073 shares of the biotechnology company’s stock after buying an additional 89,633 shares during the quarter. Innoviva comprises 1.0% of Systematic Financial Management LP’s portfolio, making the stock its 21st largest holding. Systematic Financial Management LP’s holdings in Innoviva were worth $38,216,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in shares of Innoviva by 1.5% in the second quarter. Dimensional Fund Advisors LP now owns 4,684,594 shares of the biotechnology company’s stock valued at $76,826,000 after buying an additional 71,336 shares during the last quarter. American Century Companies Inc. increased its holdings in Innoviva by 369.6% in the second quarter. American Century Companies Inc. now owns 459,690 shares of the biotechnology company’s stock valued at $7,539,000 after buying an additional 361,797 shares in the last quarter. Denali Advisors LLC grew its position in shares of Innoviva by 34.9% in the second quarter. Denali Advisors LLC now owns 439,786 shares of the biotechnology company’s stock valued at $7,212,000 after purchasing an additional 113,700 shares during the last quarter. Marshall Wace LLP boosted its position in Innoviva by 823.3% during the second quarter. Marshall Wace LLP now owns 204,752 shares of the biotechnology company’s stock worth $3,358,000 after acquiring an additional 182,575 shares during the last quarter. Finally, Assetmark Inc. boosted its position in Innoviva by 4.9% during the third quarter. Assetmark Inc. now owns 154,890 shares of the biotechnology company’s stock worth $2,991,000 after acquiring an additional 7,168 shares during the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Stock Performance

NASDAQ:INVA opened at $18.87 on Thursday. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38. The company has a market cap of $1.18 billion, a P/E ratio of 27.35 and a beta of 0.53. Innoviva, Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $21.28. The firm’s 50 day moving average is $19.55 and its two-hundred day moving average is $18.28.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The company had revenue of $89.51 million for the quarter. Analysts expect that Innoviva, Inc. will post 0.33 EPS for the current year.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.